The late phase respiratory and cardiac safety study will involve 14,000 patients across 750 sites, the company's largest such trial in its history.
iCardiac, a core laboratory for cardiac safety and respiratory services, has begun enrolling patients in the company's largest-ever late phase respiratory and cardiac safety study. The three-year trial will be conducted at sites in 28 countries and will include about 340,000 pulmonary function tests and 90,000 ECG reviews, according to iCardiac.
In July 2015, the company acquired the clinical trials division of nSpire Health (read background on the deal here).
Read the full release.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.